C. Sweeney

Statistics

Publications

Citations

104

H-Index

Active since

2004

Affiliations

Indiana University – Purdue University Indianapolis(Current)

C. Sweeney is an author at Indiana University – Purdue University Indianapolis specializing in pharmacology, toxicity management, and dose-limiting toxicity assessment.

ORCID

Publications per year

2004–2010

Publications

Hepatitis A virus and injecting drug misuse in Aberdeen, Scotland: a case–control study

K. Roy, H. Howie, C. Sweeney et al. · Journal of Viral Hepatitis · 2004 · 30 citations

Public Health, Infectious Disease Control, Infectious Diseases +12

A phase I, pharmacokinetic (PK), and preliminary efficacy assessment of ALD518, a humanized anti-IL-6 antibody, in patients with advanced cancer

Stephen Clarke, Jeff Smith, Clare Gebbie et al. · Journal of Clinical Oncology · 2009 · 25 citations

Pharmacy, Oncology, Pharmacology +15

Interim results from a first-in-human study with AMG102, a fully human monoclonal antibody that neutralizes hepatocyte growth factor (HGF), the ligand to c-Met receptor, in patients (pts) with advanced solid tumors

Michael S. Gordon, David S. Mendelson, C. Sweeney et al. · Journal of Clinical Oncology · 2007 · 23 citations

Medicine, Oncology, Pharmacology +17

Phase I dose escalation study to determine the safety, pharmacokinetics and pharmacodynamics of BMS-582664, a VEGFR/FGFR inhibitor in patients with advanced/metastatic solid tumors

Lee S. Rosen, G. Wilding, C. Sweeney et al. · Journal of Clinical Oncology · 2006 · 14 citations

Medicine, Oncology, Pharmacology +17

Mature results from Hoosier Oncology Group GU04-75 phase II trial of cisplatin (C), gemcitabine (G), and bevacizumab (B) as first-line chemotherapy for metastatic urothelial carcinoma (UC).

Noah M. Hahn, Walter M. Stadler, Robin Zoň et al. · Journal of Clinical Oncology · 2010 · 12 citations

Medicine, Pharmacology, Pharmacotherapy +15

1–5 of 5